Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis
Open Access
- 13 September 2022
- journal article
- review article
- Published by Springer Nature in Pain and Therapy
- Vol. 11 (4) , 1113-1136
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurologic complication of chemotherapy, resulting in symptoms like pain, sensory loss, and numbness in the hands and feet that cause lots of uneasiness in patients with cancer. They often suffer from pain so severe that it interrupts the treatment, thus invalidating the entire chemotherapy-based healing process, and significantly reducing their quality of life. In this paper, we underline the role of the complement system in CIPN, highlighting the relevance of the C5a fragment and its receptor C5aR1, whose activation is thought to be involved in triggering a cascade of events that can lead to CIPN onset. Recent experimental data showed the ability of docetaxel and paclitaxel to specifically bind and activate C5aR1, thus shining light on one of the molecular mechanisms by which taxanes may activate a cascade of events leading to neuropathy. According to these new evidence, it was possible to suggest new mechanisms underlying the pathophysiology of CIPN. Hence, the C5a/C5aR1 axis may represent a new target for CIPN treatment, and the use of C5aR1 inhibitors can be proposed as a potential new therapeutic option to manage this high unmet medical need.Keywords
Funding Information
- Ministero delle imprese e del made in Italy (F/090033/01-03-04/X36)
This publication has 181 references indexed in Scilit:
- Overview of Complement Activation and RegulationSeminars in Nephrology, 2013
- Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsSupportive Care in Cancer, 2012
- Chemokines, neuronal–glial interactions, and central processing of neuropathic painPharmacology & Therapeutics, 2010
- Nociceptive sensitization by complement C5a and C3a in mousePain, 2010
- Cytokine and Chemokine Regulation of Sensory Neuron Function2009
- Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathyAnnals of Neurology, 2008
- Treatment with DF 2162, a non‐competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in miceBritish Journal of Pharmacology, 2008
- Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory painBritish Journal of Pharmacology, 2008
- Complement-targeted therapeuticsNature Biotechnology, 2007
- Peripheral neuropathic pain—a multidimensional burden for patientsEuropean journal of pain, 2001